Key facts
as of Sep 2026- TRexBio’s last known valuation is $274.0M (Jan 2026).
- It has raised $222.1M; the latest was Later Stage VC ($50.0M) in Jan 2026.
- Notable investors include Alexandria Venture Investments, Johnson & Johnson JJDC, Polaris Partners, SV Health Investors, Pfizer Ventures — 14 tracked in total.
- 4 institutional filers report fund marks on TRexBio across 13 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for TRexBio
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in TRexBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
4 filers · latest Oct 20254 SEC-registered funds reported 13 fair-value marks on TRexBio between Apr 2025 and Oct 2025. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for TRexBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About TRexBio
Developer of immunoregulatory medicines designed to restore immune balance in inflammatory diseases through tissue regulatory T cell biology. The company offers a Deep Biology platform leveraging computational biology tools, human tissue analysis, and deep immunobiology expertise, enabling patients with inflammatory and autoimmune conditions to benefit from therapies that activate and expand tissue regulatory T cells for improved disease control.
- Sector
- Healthcare
- HQ
- South San Francisco, CA, United States
- Founded
- 2018
- Employees
- 57
- Website
- trex.bio/
- Ownership
- Privately Held (backing)